The ongoing Bundibugyo virus Ebola outbreak, declared a PHEIC by WHO in May 2026, drives market sentiment, with DRC reporting 837 confirmed cases and 196 deaths as of mid-June per CDC and ECDC data, plus 19 confirmed cases in Uganda. This marks the largest known outbreak of this strain, fueled by a likely February spillover, remote locations in Ituri and neighboring provinces, armed conflict, population displacement, and weak surveillance that delays detection and isolation. CDC models project potential growth to thousands of cases without improved containment, while low U.S. risk reflects limited international travel links and screening measures. Key upcoming factors include updated WHO/Africa CDC situation reports, revised transmission models, and any new cross-border detections that could expand the list of affected countries before year-end.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · ActualizadoWhich countries will have an Ebola case in 2026?
Which countries will have an Ebola case in 2026?
$25,248 Vol.
31 dic 2026
South Sudan
76%
Rwanda
39%
Burundi
34%
United States
23%
Canada
24%
Kenya
60%
India
35%
Republic of the Congo
17%
Nigeria
44%
Ethiopia
49%
Somalia
24%
China
11%
$25,248 Vol.
South Sudan
$641 Vol.
76%
Rwanda
$943 Vol.
39%
Burundi
$200 Vol.
34%
United States
$7,482 Vol.
23%
Canada
$907 Vol.
24%
Kenya
$193 Vol.
60%
India
$539 Vol.
35%
Republic of the Congo
$9,918 Vol.
17%
Nigeria
$25 Vol.
44%
Ethiopia
$65 Vol.
49%
Somalia
$71 Vol.
24%
China
$2,308 Vol.
11%
This market will resolve to "Yes" if there is a confirmed case of Ebola in the territory of the specified country reported between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
Any active laboratory-confirmed, or otherwise officially confirmed, Ebola infection identified within the territory of the specified country will qualify, regardless of where exposure, symptom onset, or testing occurred.
The primary resolution sources for this market will be official information from the relevant national and international health authorities; however, an overwhelming consensus of credible reporting will also suffice.The ongoing Bundibugyo virus Ebola outbreak, declared a PHEIC by WHO in May 2026, drives market sentiment, with DRC reporting 837 confirmed cases and 196 deaths as of mid-June per CDC and ECDC data, plus 19 confirmed cases in Uganda. This marks the largest known outbreak of this strain, fueled by a likely February spillover, remote locations in Ituri and neighboring provinces, armed conflict, population displacement, and weak surveillance that delays detection and isolation. CDC models project potential growth to thousands of cases without improved containment, while low U.S. risk reflects limited international travel links and screening measures. Key upcoming factors include updated WHO/Africa CDC situation reports, revised transmission models, and any new cross-border detections that could expand the list of affected countries before year-end.
This market will resolve to "Yes" if there is a confirmed case of Ebola in the territory of the specified country reported between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
Any active laboratory-confirmed, or otherwise officially confirmed, Ebola infection identified within the territory of the specified country will qualify, regardless of where exposure, symptom onset, or testing occurred.
The primary resolution sources for this market will be official information from the relevant national and international health authorities; however, an overwhelming consensus of credible reporting will also suffice.
Any active laboratory-confirmed, or otherwise officially confirmed, Ebola infection identified within the territory of the specified country will qualify, regardless of where exposure, symptom onset, or testing occurred.
The primary resolution sources for this market will be official information from the relevant national and international health authorities; however, an overwhelming consensus of credible reporting will also suffice.
Mercado abierto: May 22, 2026, 12:35 PM ET
Volumen
$25,248Fecha de finalización
31 dic 2026Mercado abierto
May 22, 2026, 12:35 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if there is a confirmed case of Ebola in the territory of the specified country reported between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
Any active laboratory-confirmed, or otherwise officially confirmed, Ebola infection identified within the territory of the specified country will qualify, regardless of where exposure, symptom onset, or testing occurred.
The primary resolution sources for this market will be official information from the relevant national and international health authorities; however, an overwhelming consensus of credible reporting will also suffice.The ongoing Bundibugyo virus Ebola outbreak, declared a PHEIC by WHO in May 2026, drives market sentiment, with DRC reporting 837 confirmed cases and 196 deaths as of mid-June per CDC and ECDC data, plus 19 confirmed cases in Uganda. This marks the largest known outbreak of this strain, fueled by a likely February spillover, remote locations in Ituri and neighboring provinces, armed conflict, population displacement, and weak surveillance that delays detection and isolation. CDC models project potential growth to thousands of cases without improved containment, while low U.S. risk reflects limited international travel links and screening measures. Key upcoming factors include updated WHO/Africa CDC situation reports, revised transmission models, and any new cross-border detections that could expand the list of affected countries before year-end.
This market will resolve to "Yes" if there is a confirmed case of Ebola in the territory of the specified country reported between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
Any active laboratory-confirmed, or otherwise officially confirmed, Ebola infection identified within the territory of the specified country will qualify, regardless of where exposure, symptom onset, or testing occurred.
The primary resolution sources for this market will be official information from the relevant national and international health authorities; however, an overwhelming consensus of credible reporting will also suffice.
Any active laboratory-confirmed, or otherwise officially confirmed, Ebola infection identified within the territory of the specified country will qualify, regardless of where exposure, symptom onset, or testing occurred.
The primary resolution sources for this market will be official information from the relevant national and international health authorities; however, an overwhelming consensus of credible reporting will also suffice.
Volumen
$25,248Fecha de finalización
31 dic 2026Mercado abierto
May 22, 2026, 12:35 PM ETResolver
0x65070BE91...The ongoing Bundibugyo virus Ebola outbreak, declared a PHEIC by WHO in May 2026, drives market sentiment, with DRC reporting 837 confirmed cases and 196 deaths as of mid-June per CDC and ECDC data, plus 19 confirmed cases in Uganda. This marks the largest known outbreak of this strain, fueled by a likely February spillover, remote locations in Ituri and neighboring provinces, armed conflict, population displacement, and weak surveillance that delays detection and isolation. CDC models project potential growth to thousands of cases without improved containment, while low U.S. risk reflects limited international travel links and screening measures. Key upcoming factors include updated WHO/Africa CDC situation reports, revised transmission models, and any new cross-border detections that could expand the list of affected countries before year-end.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · Actualizado
Cuidado con los enlaces externos.
Cuidado con los enlaces externos.
Preguntas frecuentes